TARSUS PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
TARSUS PHARMACEUTICALS, INC. (TARS) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $37.53 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2024-11-13
- TARSUS PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $24.50M, a 52.66% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-06-30 was $10.54M, a 83.75% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-03-31 was $2.50M, a 93.80% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2023-09-30 was $51.74M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2024-09-30 | $24.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $35.03M derived: sum of 2 quarters · filed 2024-11-13 | $37.53M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $10.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $13.04M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.50M 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $51.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $116.62M derived: sum of 2 quarters · filed 2024-11-13 | $156.92M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $64.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $105.18M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $40.30M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |